Evotec AG has achieved a twelfth milestone in its research alliance with Boehringer Ingelheim, triggering a $2.9 million payment to Evotec. The milestone was for the transition of an oncology program into lead optimization. Dr. Mario Polywka, chief operating officer of Evotec said, “This is the twelfth milestone achieved as part of this alliance with Boehringer Ingelheim and the third against an oncology target. We are now in our eighth year of this collaboration and this milestone agai...